Translation, Cultural Adaptation and Validation of the Brazilian Version of the Alopecia Areata Quality of Life Index

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

An arthritis drug, Rinvoq, restores hair in some alopecia areata patients but is not effective for androgenetic alopecia. It is used for autoimmune-related skin disorders, but its high cost and lack of insurance coverage are issues.

People are looking forward to improved self-confidence and freedom from weather-related hair concerns after hair restoration. Treatments mentioned include medications and hair transplants.

The conversation discusses alopecia areata and whether diet changes can resolve it. One user mentions that their condition fluctuates without dietary changes, suggesting stress as a possible factor.

An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.